Gilead Sciences Q1 2024 Adj EPS $(1.32) Beats $(1.49) Estimate, Sales $6.10B Miss $6.34B Estimate
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences reported Q1 2024 adjusted EPS of $(1.32), surpassing the $(1.49) estimate, but its sales of $6.10B fell short of the $6.34B forecast, marking a 3.97% year-over-year decrease.
April 25, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Gilead Sciences exceeded EPS estimates but missed on sales for Q1 2024, with a slight decrease in sales compared to last year.
While beating EPS estimates typically has a positive impact on stock prices, missing sales forecasts and reporting a year-over-year decrease in sales could temper investor enthusiasm. The mixed results present a neutral outlook in the short term as investors weigh the significance of the earnings beat against the sales miss.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100